Urology journal, cilt.16, sa.5, ss.453-457, 2019 (SCI-Expanded)
Purpose: To investigate the prognostic role of time to castration resistance(TTCR) in patients who have received solely Docetaxel chemotherapy regimen(DCR) for castration resistant prostate cancer(CRPC).